« Förderinformationen

Patient non-adherence to prescribed treatment is an issue that affects patient health outcomes and healthcare system costs worldwide. It is estimated that it contributes to 200 000 premature deaths in the EU each year, and the annual costs of avoidable hospitalisations, emergency care and adult outpatient visits are assessed at EUR 125 billion. Addressing the issues of adherence would significantly improve both individual patient outcomes and reduce societal costs.
Many researchers have approached the topic of adherence but insights have necessarily been limited to specific sub-topics due to the breadth of the field. Unless the underlying problem is well-defined and understood, the probability of developing effective solutions with broad and consistent impact is low.

Consequently, there is a need to generate a more comprehensive theoretical and empirical understanding of the underlying causes of these patient behaviours and any interactions. This topic proposes the creation of a generalised model, grounded in behavioural theory, which integrates significant factors affecting non-adherent behaviour. This would provide a robust definition of the problem - a foundation for understanding and predicting patient behaviour - and guidance to develop and implement cost-effective tools and solutions for patients, healthcare professionals (HCPs) and other healthcare stakeholders, which directly target the causes of non-adherence and, ultimately, improve patient outcomes and reduce health system costs.
Creating the necessary understanding for an effective model will require broad engagement and skills, particularly since we are targeting a disease agnostic model. The perspectives of patients, healthcare providers, academic experts, behavioural scientists, digital and data analytics experts, and regulatory bodies will be essential to maximise the benefits and ensure all sectors of society are well served.

The aims of the Call topic are to:
o develop a comprehensive understanding of the factors which affect patient needs and adherence, independently from the therapeutic area (i.e. generic or disease-agnostic), in a real-world context (as opposed to clinical setting);
o identify the most significant factors;
o evaluate existing models and then either create an open access behavioural model or further develop an existing model;
o collect additional real-world data to refine the model;
o provide tools that will enable healthcare stakeholders to cost-effectively develop and implement solutions to address patient needs and improve adherence rates.

A behavioural model will be created or selected and refined. In parallel, adherence modules will be added to existing patient studies to fill identified gaps in the data.
While disease-agnostic, the model should be able to increase the prediction power and accuracy when applying additional, disease-specific inputs.

Once developed or refined, the model will be validated for multiple ages (including paediatric), ethnicities and conditions. It is anticipated that this shall be achieved using the following therapeutic areas, dependent on access to patients provided by members of the consortium:
o Cardiovascular;
o Oncology;
o Immunology;
o Neurology;
o Endocrinology and
o Rare Disease.
This list is not exhaustive. Where opportunities arise to validate in other additional therapeutic areas, these should be explored.

The call has 2 stages.

Further information:
https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/imi2-2020-23-06;freeTextSearchKeyword=;typeCodes=1,0;statusCodes=31094501,31094502,31094503;programCode=H2020;programDivisionCode=null;focusAreaCode=null;crossCuttingPriorityCode=null;callCode=Default;sortQuery=submissionStatus;orderBy=asc;onlyTenders=false;topicListKey=topicSearchTablePageState

https://www.imi.europa.eu/sites/default/files/uploads/documents/apply-for-funding/open-calls/IMI2_Call23_CallText.pdf